Abstract
Temozolomide (TMZ) is an alkylating agent used in the management of gliomas. Although TMZ is generally safe and acute toxicity is well documented, there are limited data on long-term toxicities. We present three patients with glioma; all patients started on TMZ after having progressed following primary treatment. These patients have continued TMZ for 5 years, 7 years and 8 years respectively. So far they have had no serious side effects. We discuss these patients while raising the question of prolonged TMZ use.
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Alkylating / adverse effects*
-
Astrocytoma / drug therapy
-
Astrocytoma / radiotherapy
-
Astrocytoma / surgery
-
Brain / drug effects
-
Brain / pathology
-
Brain Neoplasms / drug therapy*
-
Brain Neoplasms / radiotherapy
-
Brain Neoplasms / surgery
-
Dacarbazine / administration & dosage
-
Dacarbazine / adverse effects
-
Dacarbazine / analogs & derivatives*
-
Drug-Related Side Effects and Adverse Reactions*
-
Glioblastoma / drug therapy
-
Glioblastoma / radiotherapy
-
Glioblastoma / surgery
-
Glioma / drug therapy*
-
Glioma / radiotherapy
-
Glioma / surgery
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / prevention & control
-
Neurosurgical Procedures / methods
-
Radiotherapy / methods
-
Retrospective Studies
-
Temozolomide
-
Time
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Alkylating
-
Dacarbazine
-
Temozolomide